Bioqual

Executive Summary

Bioqual, founded in 1981 and headquartered in Rockville, Maryland, is a preclinical contract research organization (CRO) specializing in infectious disease, oncology, and immunogenicity studies. The company provides comprehensive in vivo and in vitro services using small and large animal models, supporting drug discovery from early R&D through IND-enabling studies. With over four decades of experience, Bioqual serves both commercial and government clients, positioning itself as a trusted partner in preclinical development. As a private company, it has steadily grown its capabilities, though specific financial and operational details remain undisclosed. Given its niche focus and government clientele, Bioqual is well-positioned to benefit from increased R&D spending in infectious diseases and oncology, particularly in the post-pandemic era. Its established infrastructure and expertise in animal models provide a competitive advantage in the CRO market.

Upcoming Catalysts (preview)

• Q4 2025Award of New Government Contracts (e.g., NIH or DOD)70% success
• Q2 2026Expansion of Animal Model Capabilities or Facility60% success
• Q3 2026Launch of New Service Offering in Immunogenicity or Oncology50% success